Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Savva Bordalo, Joana ^a   Ramalho Carvalho, João ^a   Pinheiro, Manuela ^a   Costa, Vera L ^a   Rodrigues, Ângelo ^a   Dias, Paula C ^a   Veiga, Isabel ^a   Machado, Manuela ^a   Teixeira, Manuel R ^a,b   Henrique, Rui ^a,b   Jerónimo, Carmen ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE; DNA;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DNA METHYLATION; EPIGENETICS; ESOPHAGUS CANCER; EXON SKIPPING; FEMALE; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; MUCOSA INFLAMMATION; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROMOTER REGION; QUANTITATIVE ANALYSIS; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; GASTROINTESTINAL TUMOR; GENETICS; INTRON; MIDDLE AGED; MUTATION; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; DIHYDROURACIL DEHYDROGENASE (NADP); DNA METHYLATION; DNA, NEOPLASM; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GENE REARRANGEMENT; HUMANS; INTRONS; MALE; MIDDLE AGED; MUCOSITIS; MUTATION; NEOPLASM STAGING; NEUTROPENIA; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 77956472030     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-470     Document Type: Article

References (32)

1. Longley D, Harkin DP, Johnston P. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338. 10.1038/nrc1074, 12724731.
2. Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980, 104:309-319. 10.1002/jcp.1041040305, 7419607.
3. Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004, 15:1025-1032. 10.1093/annonc/mdh264, 15205195.
4. Perry MC. The Chemotherapy Source Book. 2008, Lippincott Williams & Wilkins, 4.
5. UpToDate Online 17.1. , http://www.uptodate.com
6. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008, 26:2131-2138. 10.1200/JCO.2006.10.4182, 18299612.
7. Harstrick A, Gonzales A, Schleucher N, Vanhoefer U, Lu K, Formento JL, Milano G, Wilke H, Seeber S, Rustum Y. Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance. Anti-Cancer Drugs 1998, 9:625-634. 10.1097/00001813-199808000-00008, 9773807.
8. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003, 9:786-791.
9. Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Annals of Oncology 2008, 19:915-919. 10.1093/annonc/mdm599, 2931808, 18245778.
10. Ezzeldin HH, Diasio R. Predicting fluorouracil toxicity: can we finally do it?. J Clin Oncol 2008, 26:2080-2082. 10.1200/JCO.2007.15.5481, 18299611.
11. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004, 40:939-950. 10.1016/j.ejca.2003.12.004, 15093568.
12. Maekawa K, Saeki M, Saito Y, Ozawa S, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Kato K, Hamaguchi T, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 2007, 52(10):804-819. 10.1007/s10038-007-0186-6, 17828463.
13. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000, 10(3):217-223. 10.1097/00008571-200004000-00002, 10803677.
14. Raida M, Schwabe W, Häusler P, van Kuilenburg AB, van Gennip AH, Behnke D, Höffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001, 7:2832-2839.
15. van Kuilenburg AB, Meijer J, Mul AN, Hennekam RC, Hoovers JM, de Die-Smulders CE, Weber P, Mori A, Bierau J, Fowler B, et al. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3). Hum Genet 2009, 125:581-590. 10.1007/s00439-009-0653-6, 19296131.
16. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K, Nishiyama M. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004, 10:7100-7107. 10.1158/1078-0432.CCR-04-0337, 15501990.
17. Ezzeldin HH, Lee AM, Mattison LK, Diasio R. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005, 11:8699-8705. 10.1158/1078-0432.CCR-05-1520, 16361556.
18. Zhang X, Soong R, Wang K, Li L, Davie J, Guarcello V, Diasio R. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem Cell Biol 2007, 85:337-346. 10.1139/O07-009, 17612628.
19. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 2009, Institute. UDoHaHSNIoHNC.
20. Stanley R, Hamilton LAA. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours 2000,
21. Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol 2003, 226:33-34.
22. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994, 22:2990-2997. 10.1093/nar/22.15.2990, 310266, 8065911.
23. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298. 10.1038/nrg2005, 17339880.
24. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996, 24:5064-5066. 10.1093/nar/24.24.5064, 146326, 9016686.
25. Dugast-Darzacq C, Grange T. MethylQuant: a real-time PCR-based method to quantify DNA methylation at single specific cytosines. Methods Mol Biol 2009, 507:281-303. full_text, 18987822.
26. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001, 61(8):3410-3418.
27. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002, 30(12):e57. 10.1093/nar/gnf056, 117299, 12060695.
28. Amstutz U, Farese S, Aebi S, Largiadèr C. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 2008, 27:54. 10.1186/1756-9966-27-54, 2584619, 18937829.
29. Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon M, Sanches E, dos Santos JG, Teixeira M, Castedo S. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genetics in Medicine 2004, 6:102-107. 10.1097/01.GIM.0000118061.66602.A5, 15017333.
30. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003, 8(3):132-138. 10.1007/s10147-003-0330-z, 12851836.
31. Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother Pharmacol 2009, 64(3):615-618. 10.1007/s00280-009-0970-4, 19288105.
32. Paré L, Paez D, Salazar J, Rio E, Tizzano E, Marcuello E, Baiget M. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with a 5FU-based chemotherapy. British Journal of Clinical Pharmacology 2010,